Selank: What the Research Actually Shows

What It Is

A Synthetic Analog of Tuftsin, Built the Same Way as Semax

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide built from tuftsin, a naturally occurring immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of immunoglobulin G, with the same Pro-Gly-Pro tripeptide added to the end that stabilizes Semax against rapid breakdown. It was developed by the Institute of Molecular Genetics at the Russian Academy of Sciences, the same group (led by Nikolai Myasoedov) responsible for Semax, and is formulated the same way, as an intranasal spray, for the same reason: to reach the central nervous system without depending on the peptide surviving oral digestion or first-pass liver metabolism. In Russia, Selank has a clinical use history as an anxiolytic for generalized anxiety disorder and neurasthenia (a diagnosis roughly corresponding to persistent fatigue with anxiety and irritability), a use history that reflects Russian regulatory practice and clinical tradition, not FDA review of randomized efficacy data.

The Evidence

A Real Enkephalin-Preserving Mechanism, One Non-Randomized Human Trial, and a Marketing Claim That Didn't Hold Up

Mechanism: Inhibiting the Enzymes That Break Down Enkephalins

Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB. "The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity." Bulletin of Experimental Biology and Medicine. 2001;131:315-317. doi: 10.1023/a:1017979514274. This study found that patients with various anxiety and phobic disorders, including generalized anxiety, had a shortened half-life of circulating leu-enkephalin alongside reduced activity of the enzymes that normally regulate its breakdown. Selank dose-dependently inhibited the enzymatic hydrolysis of plasma enkephalin in this system, and did so more potently than comparable peptidase inhibitors tested. The proposed mechanism is straightforward: by slowing the breakdown of the body's own enkephalins (opioid-family peptides involved in mood and stress regulation), Selank may indirectly extend their signaling, distinct from directly activating a receptor itself. This is a real, specific biochemical mechanism, not a directly measured behavioral or clinical outcome.

Human Plasma/Enzymatic Study · Endpoint: Enkephalin-Degrading Enzyme Activity, Not a Behavioral or Clinical Outcome Measure

Animal Mechanism: BDNF Regulation in the Rat Hippocampus

Inozemtseva LS, Karpenko EA, Dolotov OV, et al. "Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo." Doklady Biological Sciences. 2008;421:241-243. doi: 10.1134/s0012496608040066. Following the same pattern established with Semax, this study found that intranasal Selank altered BDNF expression in the rat hippocampus. This gives Selank a second, independent proposed mechanism (neurotrophic signaling, alongside the enkephalin-preservation mechanism above), but like the equivalent Semax findings, it is rodent-only data. No published human study has measured whether Selank changes BDNF levels or activity in people.

Rat Model, Mechanistic · Endpoint: Hippocampal BDNF Expression, Rodent Only

Human Clinical Study in Generalized Anxiety Disorder and Neurasthenia

Zozulia AA, Neznamov GG, Siuniakov TS, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48. PMID: 18454096. This Russian clinical study compared Selank (30 patients) against medazepam, a benzodiazepine-class anxiolytic (32 patients), in patients diagnosed with generalized anxiety disorder or neurasthenia. Both treatments produced similar anxiolytic effects, and Selank additionally showed antiasthenic (anti-fatigue) and mild psychostimulant effects that medazepam did not. The study also found that patients with more severe anxiety and neurasthenia had a shorter enkephalin half-life at baseline, and that this normalized with treatment, consistent with the enzymatic mechanism above. The available record does not describe randomization or blinding, so, following the same standard applied to the Semax stroke studies, this should be read as a comparative clinical study within Russian clinical practice, not a controlled trial by modern standards.

Human Clinical Study, GAD/Neurasthenia (n=62) · Endpoint: Anxiolytic Symptom Scores vs. Active Comparator, Randomization/Blinding Not Reported

Testing (and Not Confirming) the GABA Claim

Filatova EV, Kasian AA, Kolomin TA, et al. "GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells." Frontiers in Pharmacology. 2017;8:89. doi: 10.3389/fphar.2017.00089. This study directly tested a claim that circulates widely in Selank marketing, that it acts as a nootropic through the GABA (gamma-aminobutyric acid) system, by measuring the expression of GABAergic-pathway genes in a human neuroblastoma cell line (IMR-32) exposed to Selank, GABA itself, and olanzapine for comparison. The result: Selank had no direct effect on the mRNA levels of the GABAergic system genes tested. This is worth stating plainly because it directly contradicts a claim that shows up across vendor and marketing content: the best-supported mechanism for Selank is enkephalin preservation (above), not direct GABAergic modulation, and the one study that tested the GABA claim in a controlled way did not confirm it.

Human Cell Line (IMR-32), In Vitro · Endpoint: GABAergic Gene Expression, Selank Showed No Direct Effect

Sources

References